National Institutes of Health: Polycythemia trials
The registry lists 10 Polycythemia studies with National Institutes of Health as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 4Phase 2 4No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
- Lenalidomide and Prednisone in Treating Patients With MyelofibrosisCompletedNCT00227591Phase 2Results posted
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 1
- Pulmonary Hypertension, Hypoxia and Sickle Cell DiseaseCompletedNCT00495638
- Molecular Changes and Biomarkers in Chronic Myeloproliferative DisordersCompletedNCT00433862
- Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00357305Phase 1
- Tipifarnib in Treating Patients With Myelofibrosis and Myeloid MetaplasiaCompletedNCT00047190Phase 2
- Imatinib Mesylate in Treating Patients With MyelofibrosisCompletedNCT00039416Phase 2
- Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1